Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
Sci Adv
; 8(8): eabi6110, 2022 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1714330
ABSTRACT
The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Canabidiol
/
Interações Hospedeiro-Patógeno
/
SARS-CoV-2
/
Imunidade Inata
Tipo de estudo:
Estudo de coorte
/
Estudo experimental
/
Estudo observacional
/
Estudo prognóstico
/
Ensaios controlados aleatorizados
Limite:
Animais
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Sci Adv
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
Sciadv.abi6110
Similares
MEDLINE
...
LILACS
LIS